We are live on
!
Find out more
E
Ergoteles Portfolio holdings
AUM
$68.2M
1-Year Est. Return
36.16%
This Fund
S&P 500
This Quarter
Est. Return
+13.32%
1 Year Est. Return
+36.16%
3 Year Est. Return
+76.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.72B
AUM Growth
-$123M
(-4.3%)
Cap. Flow
-$215M
Cap. Flow
% of AUM
-7.9%
Top 10 Holdings %
Top 10 Hldgs %
16.65%
Holding
2,200
New
704
Increased
294
Reduced
353
Closed
800
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$85.8M |
| 2 |
Steel Dynamics
STLD
|
+$50.2M |
| 3 |
McKesson
MCK
|
+$43.7M |
| 4 |
STOR
STORE Capital Corporation
STOR
|
+$38.2M |
| 5 |
Arch Capital
ACGL
|
+$26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTXS
Citrix Systems Inc
CTXS
|
+$149M |
| 2 |
DRE
Duke Realty Corp.
DRE
|
+$147M |
| 3 |
NLSN
Nielsen Holdings plc
NLSN
|
+$44.3M |
| 4 |
CoStar Group
CSGP
|
+$44.2M |
| 5 |
Chevron
CVX
|
+$43.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 15.28% |
| 2 | Healthcare | 12.35% |
| 3 | Industrials | 12.24% |
| 4 | Technology | 10.34% |
| 5 | Consumer Discretionary | 10.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLSD
1276
DELISTED
Clearside Biomedical
CLSD
| $61.4K | ﹤0.01% |
+3,657
| New | +$65.9K |
|
1277
GrafTech
EAF
$197M
| $60.6K | ﹤0.01% |
+1,274
| New | +$61.9K |
|
|
KLRS
1278
Kalaris Therapeutics
KLRS
$84M
| $60.3K | ﹤0.01% |
+511
| New | +$86.7K |
|
1279
Q32 Bio
QTTB
$452M
| $59.1K | ﹤0.01% |
2,605
-3,444
| -57% | -$91.4K |
|
|
CAMP
1280
DELISTED
CalAmp Corp.
CAMP
| $57.7K | ﹤0.01% |
560
-8,674
| -94% | -$733K |
|
|
ALP
1281
Alpha Compute
ALP
$4.74M
| $56.5K | ﹤0.01% |
543
-487
| -47% | -$59.6K |
|
1282
Akebia Therapeutics
AKBA
$333M
| $56.3K | ﹤0.01% |
97,521
-67,716
| -41% | -$21.2K |
|
1283
Werewolf Therapeutics
HOWL
$22.1M
| $54.3K | ﹤0.01% |
26,501
-88,094
| -77% | -$230K |
|
|
AGEN
1284
Agenus
AGEN
$267M
| $54.1K | ﹤0.01% |
1,148
-6,041
| -84% | -$307K |
|
1285
Carvana
CVNA
$45.8B
| $53.8K | ﹤0.01% |
56,760
-54,890
| -49% | -$116K |
|
|
ME
1286
DELISTED
23andMe Holding Co
ME
| $53.5K | ﹤0.01% |
+1,239
| New | +$72.1K |
|
|
PCTI
1287
DELISTED
PCTEL, Inc. Common Stock
PCTI
| $52.5K | ﹤0.01% |
+12,217
| New | +$54.5K |
|
1288
Passage Bio
PASG
$14.4M
| $52.2K | ﹤0.01% |
1,890
-1,913
| -50% | -$48.3K |
|
1289
Wheels Up
UP
$207M
| $52.2K | ﹤0.01% |
+253
| New | +$65.2K |
|
1290
Aveanna Healthcare
AVAH
$2.13B
| $51.8K | ﹤0.01% |
66,455
+19,778
| +42% | +$20.7K |
|
|
FTH
1291
Faeth Therapeutics
FTH
$731M
| $51.2K | ﹤0.01% |
1,717
-2,781
| -62% | -$81.8K |
|
|
CYT
1292
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $49.7K | ﹤0.01% |
+30,148
| New | +$48.4K |
|
|
PRTK
1293
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $49.7K | ﹤0.01% |
26,601
-82,312
| -76% | -$205K |
|
1294
Offerpad Solutions
OPAD
$19.4M
| $48.4K | ﹤0.01% |
701
+500
| +249% | +$57.7K |
|
|
DBTX
1295
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| $48.1K | ﹤0.01% |
+23,480
| New | +$71.5K |
|
|
EMKR
1296
DELISTED
Emcore Corp
EMKR
| $48.1K | ﹤0.01% |
4,995
-10,187
| -67% | -$145K |
|
|
ADVM
1297
DELISTED
Adverum Biotechnologies
ADVM
| $47.8K | ﹤0.01% |
8,250
-28,618
| -78% | -$217K |
|
|
SQZ
1298
DELISTED
SQZ Biotechnologies Company
SQZ
| $47.5K | ﹤0.01% |
64,215
-34,744
| -35% | -$75.9K |
|
|
CYPH
1299
Cypherpunk Technologies Inc
CYPH
$65.3M
| $47.5K | ﹤0.01% |
+10,560
| New | +$70.6K |
|
|
IMA
1300
ImageneBio Inc
IMA
$63.7M
| $46.8K | ﹤0.01% |
1,467
-6,920
| -83% | -$221K |
|
Similar funds
ROC
IVMX
AM
JCG
JAMONY
FA
VCM
MCMI
Ergoteles's Q4 2022 Portfolio in Review
As of Q4 2022, Ergoteles held 2,200 positions worth $2.72B, down 4.3% from $2.85B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Ergoteles withdrew a net $215M in Q4 2022, closing 800 positions and reducing 353 holdings. Its most notable exit was Citrix Systems Inc, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Ergoteles opened a new position in McKesson worth $43.9M.
- Ergoteles's largest Q4 2022 buy was McKesson: 117,079 shares worth $43.9M.
- Ergoteles added most to iShares Biotechnology ETF in Q4 2022, an estimated $85.8M increase.
- Ergoteles's biggest Q4 2022 reduction was Alphabet (Google) Class C, cutting an estimated $41.8M.
- Ergoteles fully exited Citrix Systems Inc in Q4 2022, selling an estimated $149M.
- Ergoteles's ten largest holdings make up 17% of its $2.72B portfolio in Q4 2022.
- Ergoteles opened 704 new positions and closed 800 in Q4 2022.
- Ergoteles's portfolio value fell 4.3% quarter-over-quarter to $2.72B.
Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.